Haleon (LON:HLN) Releases Earnings Results

Haleon (LON:HLN) released its earnings results on Thursday. The company reported GBX 8.60 earnings per share for the quarter, Digital Look Earnings reports. Haleon had a net margin of 15.11% and a return on equity of 10.30%.

Haleon Stock Down 2.9%

HLN traded down GBX 11.10 during trading on Thursday, hitting GBX 368.60. 27,201,275 shares of the company’s stock traded hands, compared to its average volume of 28,030,555. The stock has a market capitalization of £32.46 billion, a price-to-earnings ratio of 19.92, a PEG ratio of 1.49 and a beta of 0.24. The company’s 50 day simple moving average is GBX 348.92 and its two-hundred day simple moving average is GBX 363.11. Haleon has a 12-month low of GBX 317.80 and a 12-month high of GBX 416.10. The company has a current ratio of 0.92, a quick ratio of 0.93 and a debt-to-equity ratio of 52.26.

Analyst Ratings Changes

HLN has been the topic of several research reports. Berenberg Bank reissued a “buy” rating and set a GBX 512 price objective on shares of Haleon in a research note on Thursday, April 30th. Jefferies Financial Group lowered their target price on shares of Haleon from GBX 450 to GBX 400 and set a “buy” rating for the company in a report on Tuesday, May 5th. Deutsche Bank Aktiengesellschaft reissued a “sell” rating and issued a GBX 325 price target on shares of Haleon in a research report on Wednesday, July 1st. JPMorgan Chase & Co. reduced their price objective on Haleon from GBX 335 to GBX 315 and set an “underweight” rating for the company in a research report on Thursday, June 25th. Finally, Royal Bank Of Canada reiterated a “sector perform” rating and set a GBX 370 price objective on shares of Haleon in a research note on Thursday, April 30th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Haleon currently has an average rating of “Hold” and an average price target of GBX 393.67.

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.